Spectrum Of Activity
Infection by Onchocerca volvulus, non-adult stage 150 mcg/kg PO (1 dose); re-treatment intervals 3 and 12m
Infestation by Phthirus pubis 250 mcg/kg PO (1 dose) with food; repeat in 14d
Intestinal strongyloidiasis 200 mcg/kg PO (1 dose)
- If evidence of larvae still present during 3m following treatment, retreat with single dose
Scabies 200 mcg/kg PO (1 dose) with food; repeat in 2w
Pediculosis capitis 0.5% lotion, apply up to 1 tube topically to dry hair
- Rinse after 10min
Rosacea, Inflammatory lesions 1% cream, apply thin film topically once dailyNo data on renal dose adjustment
Safety and efficacy of oral Ivermectin in pediatric patients BW <15 kg have not been established
Infection by Onchocerca volvulus, non-adult stage BW ≥15 kg 150 mcg/kg PO (1 dose); re-treatment intervals 3 and 12m
Intestinal strongyloidiasis BW ≥15 kg 200 mcg/kg PO (1 dose)
- If evidence of larvae still present during 3m following treatment, retreat with single doseNo data on renal dose adjustment
Infection of Onchocerca volvulus, non-adult stage
Rosacea, Inflammatory lesions
Cutaneous larva migrans
Infection by Loa loa
Infection by Wuchereria bancrofti
Infestation by Phthirus pubis
Strongyloidiasis: Obtain 1 stool culture per month for 3 months following treatment.
Onchocerciasis: Perform ophthalmic exam at baseline and periodically during treatment. Assess for loiasis prior to treatment with history of significant exposure to Loa loa-endemic areas.
Warfarin- may elevate INR values
Antimicrobial class: Anthelmintic agent, Avermectin
Pregnancy category: C
Average serum half life: 18 hours (oral), 6.5 days (topical)
Precautions: Patients with onchocerciasis may have cutaenous, allergic and inflmmatory systemic, and ophthalmological reactions during oral use.
In patients with exposure to Loa loa endemic areas, pretreatment assessment for loiasis and careful monitoring is recommended.